Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence

Fulvestrant is the first selective estrogen receptor (ER) downregulator available in clinical practice. It is a pure antiestrogen with no agonistic effects, leading to degradation of ER alpha, with activity in tamoxifen-resistant breast cancer (BC) models. Pharmacokinetic and pharmacodynamic studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocca, Andrea, Maltoni, Roberta, Bravaccini, Sara, Donati, Caterina, Andreis, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124791/
https://www.ncbi.nlm.nih.gov/pubmed/30214302
http://dx.doi.org/10.2147/CMAR.S137772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124791/
https://www.ncbi.nlm.nih.gov/pubmed/30214302
http://dx.doi.org/10.2147/CMAR.S137772

Ejemplares similares